BioCardia Announces $4.4 Million Financing

Net proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA submission; if currently outstanding warrants issued in previous financings are exercised in full for cash, it is anticipated that the cash runway would extend well beyond PMDA approval and into first commercial sales. SUNNYVALE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular